NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.
Iqvia will collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions.
This collaboration will allow NRx to access Iqvia's domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization of Zyesami.
Iqvia will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.
NRx Pharmaceuticals (NASDAQ-GS: NRXP) draws upon more than 300 combined years of scientific and drug-development experience to bring improved health to patients.
Its investigational product, Zyesami (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense.
Iqvia (NYSE: IQV) is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
With approximately 74,000 employees, Iqvia conducts operations in more than 100 countries.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval